volume 18, issue 2, P299-315 2016
DOI: 10.1016/j.jmoldx.2015.11.006
View full text
|
|
Share
Kevin E. Fisher, Linsheng Zhang, Jason Wang, Geoffrey H. Smith, Scott Newman, Thomas M. Schneider, Rathi N. Pillai, Ragini R. Kudchadkar, Taofeek K. Owonikoko, Suresh S. Ramalingam, David H. Lawson, Keith A. Delman, Bassel F. El-Rayes, Malania M. Wilson et al.

Abstract: We tested and clinically validated a targeted next-generation sequencing (NGS) mutation panel using 80 formalin-fixed, paraffin-embedded (FFPE) tumor samples. Forty non-small cell lung carcinoma (NSCLC), 30 melanoma, and 30 gastrointestinal (12 colonic, 10 gastric, and 8 pancreatic adenocarcinoma) FFPE samples were selected from laboratory archives. After appropriate specimen and nucleic acid quality control, 80 NGS libraries were prepared using the Illumina TruSight tumor (TST) kit and sequenced on the Illum…

expand abstract